Universal novel coronavirus vaccine and preparation method thereof

Abstract

The invention provides a universal novel coronavirus vaccine and a preparation method thereof. The vaccine is an artificial antigen presenting cell for expressing fusion protein of structural proteinincluding surface (S) glycoprotein, envelop (E) protein, membrane (M) protein and nucleocapsid (N) phosphoprotein and non-structural protein ORF1a polyprotein of the novel coronavirus; the vaccine simulates a natural immune system of an organism; and in the presence of cytokines, various polypeptide fragments formed by the fusion protein are presented by the antigen presenting cell, and thus, theorganism can be stimulated to generate the immune response and the immune memory is formed. The vaccine has a broad-spectrum immune stimulation effect; rapid large-scale industrial production of the vaccine can be realized; and the vaccine has the advantages of high safety and low cost.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a general-purpose novel coronavirus vaccine and a preparation method thereof. Background technique [0002] The key for the novel coronavirus (SARS-CoV-2) to infect human cells is the combination of the S protein and the ACE2 protein. In SARS virus and MERS virus, the S protein also performs the same function. Therefore, the S protein determines the host range and specificity of the virus, is an important site of action for antibodies in the host, and is also a key target for vaccines, therapeutic antibodies, and diagnostic reagents. [0003] The virus that causes COVID-19 is a new variant of coronavirus, and the spike protein (S protein) of the virus has a stronger binding ability to the receptor ACE2 than SARS-CoV, which also explains the strong infection ability of the new coronavirus. The novel coronavirus will stimulate the innate immune system of the infected person, ca...

AI Technical Summary

Problems solved by technology

The biggest challenge for vaccine development is to find a suitable animal model. At present, non-human primate infection models are mainly used to verify the safety and efficacy of vaccine development, but the cost is extremely high and time-consuming

[0004] In the existing virus vaccine technology, the whole virus antigen vaccine uses the traditional inactivated virus or attenuated virus as the antigen, which has the problems of low safety and high cost; the virus specific antigen vaccine uses the synthetic S protein as the antigen, The artificially synthesized S protein is mainly expressed by bacteria, yeast, cells, or viral vectors, which has the problems of long time-consuming, single titer, easy virus escape, short validity period, and high cost; DNA and mRNA vaccines need to enter cells and be injected into the body. It has an immune effect only after it is converted into a protein. The problem of immunogenicity is the bottleneck that this technology cannot break through at present.

Images